Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.64 |
| ▸ | HTR1A | P08908 | 7/20 | 0.64 |
| ▸ | HTR1D | P28221 | 7/20 | 0.64 |
| ▸ | HTR2A | P28223 | 6/20 | 0.64 |
| ▸ | HTR2B | P41595 | 5/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 4/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105674 | 0.90 | HTR2A (0.68) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL7000777 | 0.86 | HTR2A (0.73) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL31105758 | 0.82 | HTR2A (0.57) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL1567072 | 0.81 | HTR2A (0.59) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL1567786 | 0.81 | HTR2A (0.61) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL4688022 | 0.80 | MTNR1A (0.65) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL4690449 | 0.78 | HTR2A (1.00) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL8397290 | 0.78 | HTR2A (0.61) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL8177855 | 0.78 | HTR2C (1.00) | HTR2CHTR1AHTR1DHTR2AHTR2B | |
| SCHEMBL31105649 | 0.78 | HTR2A (0.73) | HTR2CHTR1AHTR1DHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8183285-B2 | Therapeutic agent for irritable bowel syndrome and methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2248808-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| EP-1214944-B1 | Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1997488-A1 | AGENT FOR PREVENTION/TREATMENT OF IRRITABLE BOWEL SYNDROME | Takeda Pharmaceutical Company Limited (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | HTR2C 277/4885HTR1A 67/4885HTR1D 334/4885 |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR1A 2866/4885HTR1D 3850/4885 |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR1A 2866/4885HTR1D 3850/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR1A 2866/4885HTR1D 3850/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | HTR2C 248/4885HTR1A 65/4885HTR1D 356/4885 |
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | HRH4, HRH2, HRH3 | HTR2C 223/4885HTR1A 237/4885HTR1D 197/4885 |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | HRH4, HRH2, HRH3 | HTR2C 223/4885HTR1A 237/4885HTR1D 197/4885 |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | HTR2C 25/4885HTR1A 20/4885HTR1D 33/4885 |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | HTR2C 25/4885HTR1A 20/4885HTR1D 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.